OphthaliX Successfully Completed Preclinical Studies Showing the Efficacy of CF101 for the Treatment of Anterior Uveitis


Carson City, Nevada, April 09, 2012 – OphthaliX (OTCBB: OPLI) announced today the completion of preclinical studies, showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis. The pre-clinical study data demonstrated that CF101 is efficacious in preventing the clinical manifestations of Anterior Uveitis in a well-established animal model. The current study data together with the previous published results showing the efficacy of CF101 in preventing Posterior Uveitis, strongly support the utilization of CF101 as a drug candidate for the treatment of patients with Anterior or Posterior Uveitis and as such address a larger market than either alone. This market exceeds 200,000 patients and therefore CF101 does not fall in the FDA definition of an orphan drug for the Uveitis clinical application.


Prof. Pnina Fishman, interim CEO and Chairman of OphthaliX commented: "We are very pleased with the successful preclinical study which provides additional proof for   the efficacy of CF101 in Uveitis and paves the way for a larger patient population to be treated with the drug upon successful clinical development. This will also be reflected in a larger potential market for CF101. We are currently conducting all the preparatory work for a phase 2 study in Uveitis in addition to the ongoing studies in Dry Eye Syndrome and Glaucoma. Although anterior uveitis is most often treated with topical medication, the excellent safety profile of CF101 suggests it could have a very favorable therapeutic index as a novel oral therapy in this disease”.


About OphthaliX Inc.

OphthaliX Inc. is an advanced clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. OphthaliX's product candidate, CF101, is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis.


About CF101

CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a proven efficacy in Phase 2 clinical studies and an excellent safety profile. CF101 is currently developed for ophthalmic indications. including dry eye syndrome (Phase 3), glaucoma (Phase 2) and Uveitis. CF101 is also developed for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis (Phase 2b) and psoriasis (Phase 2/3).


About Uveitis  

Uveitis is inflammation of the uvea, the middle layer of the eye that can result in blindness. Anterior uveitis refers to inflammation of the iris alone (iritis) or the iris and ciliary body. Posterior uveitis is inflammation in the retina and/or choroid. Uveitis is estimated as the fifth or sixth leading cause of blindness in the United States.  




Pnina Fishman, Interim Chief Executive Officer

Tel: +972-3-9241114

Email: pnina@ophthalix.com


This release contains forward-looking statements regarding Ophthalix’s future plans and expected performance based on assumptions the Company believes to be reasonable.  A number of risks and uncertainties could cause actual results to differ materially from these statements, including, without limitation, the success rate of business development efforts and the timeliness of development activities, and other risk factors described from time to time in the Company’s reports filed with the SEC.  In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the Company’s control. OphthaliX, Inc. undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.  The securities issued in the above transaction have not been and will not be registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.